Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

Trial Profile

C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Brain extract (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms C-REGS2
  • Sponsors EVER Neuro Pharma
  • Most Recent Events

    • 06 Feb 2019 Planned End Date changed from 30 Sep 2020 to 30 Mar 2021.
    • 06 Feb 2019 Planned primary completion date changed from 31 Mar 2020 to 30 Sep 2020.
    • 07 May 2018 Planned End Date changed from 31 Mar 2020 to 30 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top